Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion type Assertion NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_head.
- NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion description "[In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_provenance.
- NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion evidence source_evidence_literature NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_provenance.
- NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion SIO_000772 14612670 NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_provenance.
- NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion wasDerivedFrom befree-20150227 NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_provenance.
- NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_assertion wasGeneratedBy ECO_0000203 NP222703.RASvEMD2lGkV_kFcnmR6_2F0ZWfgngFq4JQpBeXNHJAYo130_provenance.